Clinical trials: Cushing Syndrome
Hypercortisolism
A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas
This is a Phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy, and safety of relacorilant to treat hypercortisolism in patients with cortisol-secreting adrenal adenoma or hyperplasia associated with…
- Trial name
- GRADIENT (NCT04308590)
- Testing
- Relacorilant
- Where
- 45 sites in United States, Austria and 7 more
- Volunteers
- 137 people
- Sponsor
- Corcept Therapeutics
Cushing Syndrome
A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome
This is a Phase 3, double-blind, placebo-controlled, randomized-withdrawal study to assess the efficacy, safety and pharmacokinetics (PK) of relacorilant in patients with endogenous Cushing syndrome and concurrent type 2 diabetes…
- Trial name
- GRACE (NCT03697109)
- Testing
- Relacorilant
- Where
- 64 sites in United States, Austria and 9 more
- Volunteers
- 152 people
- Sponsor
- Corcept Therapeutics
Cushing Syndrome, Cushing Disease
Open-label Treatment in Cushing's Syndrome
This is a long-term, open-label extension study of levoketoconazole in participants with endogenous Cushing's Syndrome.
- Trial name
- OPTICS (NCT03621280)
- Testing
- Levoketoconazole
- Where
- 30 sites in United States, Bulgaria and 9 more
- Volunteers
- 51 people
- Sponsor
- Cortendo AB
Cushing Syndrome
Modified Desmopressin (mDesmo) Using Cold-Kit for PET/CT
The incidence of Cushing syndrome (CS) is 1.2-3.2 cases per million per year, of which adrenocorticotropic Hormone (ACTH)-dependent disease comprises approximately 70-80% of cases.
- Trial name
- Ga-68 mDesmo (NCT06962202)
- Where
- India
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Cushing Syndrome, Primary Aldosteronism
Continuous Steroid Monitoring in Interstitial Fluid With Wearable and Nanoparticle-enhanced Biosensors for Improved Management of Adrenal Disorders
The goal of this project is to provide novel technology that will pave the way from the present single-point (analogue) endocrinology towards continuous cortisol and aldosterone monitoring with full time resolution.
- Conditions
- Cushing Syndrome, Primary Aldosteronism, Adrenal Insufficiency
- Trial name
- NCT06980753
- Testing
- Participants will use the biossensor for 48 h
- Where
- Brazil
- Volunteers
- 246 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo General Hospital
Obesity, Morbid
Study of the Steroid Hormone Milieu in Obese Patients
The aim of this observational study is to evaluate the actual secretion of cortisol and testosterone in obese male subjects, together with the receptor sensitivity to these hormones in order to understand whether the hormonal…
- Trial name
- MiSterO (NCT06341699)
- Where
- Italy
- Volunteers
- 180 people
- Sponsor
- Istituto Auxologico Italiano
Osteoporosis in Cushing's Syndrome, Osteoporosis in Post-menopausal Women
Cushing's Osteoporosis Specificities
Osteoporosis induced by glucocorticoids excess constitutes the main cause of secondary osteoporosis. Most of data available are provided from cohort studies of patients treated by corticosteroids, affecting among 1% of…
- Trial name
- SOCS (NCT03162068)
- Testing
- Osteodensitometry and pQCT
- Where
- France
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University Hospital, Clermont-Ferrand
Cushing Syndrome
Quality of Life, Fatigue and Cognitive, Affective and Emotional Dysfunction in Patients With Cushing's Syndrome
This is a prospective, multi-center, case-control study where neurocognitive function will be evaluated in 36 patients with Cushing syndrome (CS) and 36 controls matched for age, gender and education.
- Trial name
- NCT03211624
- Where
- 3 sites in Netherlands, Spain and 1 more
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Göteborg University
Cushing Syndrome
Cushing's Syndrome Before and After Treatment (CORRECT)
The purpose of this study is to prospectively study patients with Cushing's syndrome before and after treatment, with a special emphasis on physical function, quality of life, and circadian rhythms.
- Trial name
- CORRECT (NCT05521529)
- Testing
- no intervention, as this is an observational study
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- University of Aarhus
Adrenal Incidentaloma, Hypercortisolism
Impact of Adrenal IncidenTalomas and Possible Autonomous Cortisol Secretion on Cardiovascular and Metabolic Alterations
The investigators hypothesize that cardiovascular and metabolic alterations can occur in patients with adrenal adenomas and possible Autonomous Cortisol Secretion (pACS).
- Conditions
- Adrenal Incidentaloma, Hypercortisolism, Adrenal Tumor
- Trial name
- ITACA (NCT04127552)
- Testing
- Adrenalectomy
- Where
- Italy
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- University of Roma La Sapienza
Cushing's Syndrome
Osilodrostat for the Treatment of Non-Cushing's Disease Cushing's Syndrome
This is a multi-centre, observational, non-comparative, retrospective cohort study designed to evaluate the long-term safety and effectiveness of osilodrostat in non-CD CS patients.
- Trial name
- LINC7 (NCT05633953)
- Testing
- Osilodrostat
- Where
- France
- Volunteers
- 103 people
- Sponsor
- RECORDATI GROUP
Adrenal Incidentalomas, Cushing Syndrome
Effect of Metyrapone on Cardiovascular Risk Factors in Patients With Adrenal Incidentalomas and Cushing's Syndrome
Drug interventional, controlled, randomized open-label, parallel-group, multicenter study in patients with bilateral adrenal incidentalomas associated with subclinical Cushing's syndrome
- Trial name
- NCT06801249
- Testing
- Metarapone, Standardized antihypertensive therapy
- Where
- 3 sites in Italy
- Volunteers
- 50 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Hypercortisolism, Diabetes Mellitus, Type 2
Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST)
This is a Phase 4 study with 2 parts: Part 1 (Prevalence Phase) is non-interventional and will assess the prevalence of hypercortisolism in a population with difficult to control type 2 diabetes (T2D) (hemoglobin A1c ≥7.5%)…
- Trial name
- NCT05772169
- Testing
- Mifepristone 300 MG [Korlym]
- Where
- 36 sites in United States
- Volunteers
- 1,113 people
- Sponsor
- Corcept Therapeutics
Cushing's Syndrome
Roll-over Study in Patients With Endogenous Cushing's Syndrome for LCI699
The purpose of this study is the evaluation of long-term safety of osilodrostat in patients who have already received osilodrostat treatment in a previous Global Novartis-sponsored trial and who, based on investigators'…
- Trial name
- NCT03606408
- Testing
- osilodrostat
- Where
- 56 sites in United States, Argentina and 19 more
- Volunteers
- 127 people
- Sponsor
- RECORDATI GROUP
Cushing's Disease, Hypercortisolism
Osilodrostat Therapy and 11C-methionine PET to Improve Corticotroph Adenoma Detection
Cushing's disease is a rare condition where the body produces too much of a hormone called cortisol. Cortisol helps with metabolism, the immune system, and managing stress.
- Conditions
- Cushing's Disease, Hypercortisolism, Pituitary Adenoma, Pituitary ACTH Secreting Adenoma
- Trial name
- OPTIMAL (NCT06701838)
- Testing
- 11C-Methionine PET/CT
- Volunteers
- 15 people
- Sponsor
- Imperial College London
Cushing's Disease, Acromegaly
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
The purpose of this study is to allow continued use of pasireotide in patients who are on pasireotide treatment in a Novartis-sponsored study and are benefiting from the treatment as judged by the investigator.
- Conditions
- Cushing's Disease, Acromegaly, Neuroendocrine Tumors, Pituitary Tumors
- Trial name
- NCT01794793
- Testing
- Pasireotide, Cabergoline, Pasireotide LAR
- Where
- 94 sites in United States, Argentina and 26 more
- Volunteers
- 337 people
- Sponsor
- RECORDATI GROUP
Mineralocorticoid Excess, Primary Aldosteronism
Dynamic Hormone Profiling and Multimodal Data Capture in Primary Aldosteronism
This study is a observational study applying 24-hour microdialysis methodology to perform dynamic multisteroid adrenal hormone profiling of patients with suspected or confirmed PA.
- Conditions
- Mineralocorticoid Excess, Primary Aldosteronism, Hypercortisolism
- Trial name
- NCT06495983
- Testing
- dynamic microdialysis sampling
- Where
- Norway
- Volunteers
- 80 people
- Sponsor
- Haukeland University Hospital
Endocrine Disorders, Adiposity
Neuroendocrine Mechanisms in Adiposity: An Integrated Approach to the Characterization of Potential Pharmacological Novel Targets Based on Experimental and Clinical Models
The goal of this observational study is to evaluate, retrospectively and prospectively, the effect of different hormonal and neuropeptide dysfunctions on the body composition of patients suffering from hypothalamic-pituitary…
- Conditions
- Endocrine Disorders, Adiposity, Pituitary Adenoma, Cushing Syndrome
- Trial name
- NCT06326853
- Volunteers
- 200 people
- Sponsor
- IRCCS San Raffaele
Cushing's Syndrome
Novel Mediators of the Lipodystrophy and Metabolic Consequences of Cushing's Disease
This proposal will evaluate the glucocorticoid mediated changes in body fat distribution and metabolism that occur in patients with Cushing's disease.
- Trial name
- NCT03817840
- Testing
- Treatment of Cushing's
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Columbia University
Primary Aldosteronism, Adrenal Cushing Syndrome
Postmortem Evaluation of Adrenal and Other Endocrine Tumors in Patients With Sudden Death
Sudden Cardiac Death is a leading cause of mortality and remains a major public health burden worldwide. Cardiac arrest due to coronary heart disease explains a large proportion of the cases, but if autopsy is not performed the…
- Conditions
- Primary Aldosteronism, Adrenal Cushing Syndrome, Pheochromocytoma, Endocrine Neoplasia
- Trial name
- SuddenDeath (NCT05446779)
- Testing
- Adrenal aldosterone synthase (CYP11B2) staining, Adrenal cortisol synthase (CYP11B1) staining, Histopathological analysis
- Where
- Finland
- Volunteers
- 400 people
- Sponsor
- Helsinki University Central Hospital